Literature DB >> 1791885

Immunoregulation in man.

G T Rijkers1, B J Zegers.   

Abstract

The process during which a B lymphocyte, after ligation of the antigen receptor, differentiates into a high-rate antibody-secreting plasma cell is under strict regulatory control of T lymphocytes and their soluble products. For most so-called T-cell-dependent (protein) antigens, antigen-specific CD4-positive T cells or T-cell factors participate in the transition of resting into activated B cell. Terminal B-cell differentiation, including immunoglobulin class switch, is regulated by a variety of (antigen non-specific) cytokines which act in a highly coordinated fashion. The other major class of naturally occurring antigens, the so-called T-cell independent (polysaccharide) antigens, apparently can induce B-cell activation in the absence of antigen-specific CD4-positive T cells. Terminal B-cell differentiation, however, also depends on the action of cytokines, although the relative contribution of individual cytokines remains to be determined. Downregulation of both T-cell-dependent and T-cell independent antigens is mediated by specific suppressor T cells. Next to this "internal control" by regulatory T cells, it is important to realize that components of the (neuro-)endocrine system (such as the endorphins and the family of insulin-like growth factors) and the complement system also exert important immunoregulatory functions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1791885

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  2 in total

1.  Restoration of Retarded Influenza Virus-specific Immunoglobulin Class Switch in Aged Mice.

Authors:  Yongxin Zhang; Ying Wang; Monica Zhang; Lin Liu; Innocent N Mbawuike
Journal:  J Clin Cell Immunol       Date:  2016-03-22

Review 2.  Can antiglycolipid antibodies present in HIV-infected individuals induce immune demyelination?

Authors:  S Petratos; M E Gonzales
Journal:  Neuropathology       Date:  2000-12       Impact factor: 1.906

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.